Wednesday, June 10, 2026
πŸ‡ΊπŸ‡Έ FDA

pharma Β· Chronic Spontaneous Urticaria Β· Asthma

Novartis India

Novartis Pharmaceuticals

Novartis India clinical programs β€” 341 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Founded
1996
Employees
2,240
Programs
341
Drugs
317
Patents
0
Official website β†— All projects Drug pipeline News & analysis
Intelligence Β· Clinical Programs

Novartis India projects

341 ClinicalTrials.gov programs sponsored by Novartis India.

Novartis India has 341 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

341 programs

Clinical programs

Page 3 of 8

  1. Lapatinib

    Novartis Pharmaceuticals

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  2. Ligelizumab

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 mab completed

    1 trial

  3. NIS793

    Novartis Pharmaceuticals

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule completed

    1 trial

  4. Nilotinib

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  5. Nilotinib (AMN107)

    Novartis Pharmaceuticals

    Gastrointestinal Stromal Tumor (GIST)

    phase 3 small molecule completed

    1 trial

  6. OAV101

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 gene therapy completed

    1 trial

  7. OFC Infusion

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 small molecule completed

    1 trial

  8. Ofatumumab

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 mab terminated

    1 trial

  9. Panobinostat

    Novartis Pharmaceuticals

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  10. Pelacarsen

    Novartis Pharmaceuticals

    Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  11. Placebo

    Novartis Pharmaceuticals

    IC-MPGN

    phase 3 small molecule active

    1 trial

  12. Placebo

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 mab completed

    1 trial

  13. QAW039

    Novartis Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    1 trial

  14. QAW039 150 mg

    Novartis Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  15. QMF149

    Novartis Pharmaceuticals

    Asthma

    phase 3 small molecule active

    1 trial

  16. QMF149 150/80 ΞΌg

    Novartis Pharmaceuticals

    Mild Asthma

    phase 3 small molecule completed

    1 trial

  17. QVA149

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    1 trial

  18. QVM149 150/50/160

    Novartis Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    1 trial

  19. RAD001

    Novartis Pharmaceuticals

    Tuberous Sclerosis Complex-associated Refractory Seizures

    phase 3 small molecule completed

    1 trial

  20. Ranibizumab

    Novartis Pharmaceuticals

    Retinopathy of Prematurity

    phase 3 small molecule completed

    1 trial

  21. Ranibizumab

    Novartis Pharmaceuticals

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    1 trial

  22. Ranibizumab 0.5 mg

    Novartis Pharmaceuticals

    Central Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  23. Remibrutinib

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  24. Remibrutinib

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria

    phase 3 small molecule active

    1 trial

  25. Ribociclib

    Novartis Pharmaceuticals

    Advanced, Metastatic Breast Cancer

    phase 3 small molecule completed

    1 trial

  26. Ribociclib

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  27. Ruxolitinib

    Novartis Pharmaceuticals

    Polycythemia Vera

    phase 3 small molecule completed

    1 trial

  28. SECUKINUMAB

    Novartis Pharmaceuticals

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial

  29. SEG101

    Novartis Pharmaceuticals

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  30. Secukinumab

    Novartis Pharmaceuticals

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  31. Secukinumab

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    2 trials

  32. Secukinumab

    Novartis Pharmaceuticals

    Ankylosing Spondylitis

    phase 3 small molecule completed

    1 trial

  33. Secukinumab (75 mg)

    Novartis Pharmaceuticals

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial

  34. TQJ230

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  35. Telbivudine

    Novartis Pharmaceuticals

    Hepatitis

    phase 3 small molecule completed

    1 trial

  36. VAY736

    Novartis Pharmaceuticals

    Sjogren Syndrome

    phase 3 mab active

    1 trial

  37. VAY736F12301E1

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  38. Vildagliptin

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  39. Vildagliptin

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  40. Zoledronic acid

    Novartis Pharmaceuticals

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  41. Zoledronic acid

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  42. Zolgensma 2 Γ— 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  43. canakinumab

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 3 small molecule terminated

    2 trials

  44. ianalumab

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  45. ianalumab s.c. q4w

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule active

    1 trial

  46. secukinumab

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule terminated

    1 trial

  47. telbivudine or lamivudine

    Novartis Pharmaceuticals

    Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial

  48. zigakibart

    Novartis Pharmaceuticals

    Kidney Diseases

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Novartis India have?

341 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.